Brief: Everest Medicine In Agreement With Dimerix To Develop Commercialize DMX-200 In Greater China, South Korea, And Southeast Asia
16/06/2026 02:42
BRIEF-Everest Medicine In Agreement With Dimerix To Develop Commercialize DMX-200 In Greater China, South Korea, And Southeast Asia June 16 (Reuters) - Everest Medicines Ltd 1952.HK:
AGREEMENT WITH DIMERIX TO DEVELOP COMMERCIALIZE DMX-200 IN GREATER CHINA, SOUTH KOREA AND SOUTHEAST ASIA
DEAL INCLUDES $10 MILLION UPFRONT, UP TO $30 MILLION DEVELOPMENT MILESTONES, $300 MILLION SALES MILESTONES, 10%-15% ROYALTIES
DMX-200 RECEIVES ORPHAN DRUG DESIGNATIONS FROM FDA AND EMA
Further company coverage: 1952.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Dimerix
See all newsAustralia's Dimerix soars on commercialisation deal with Everest Medicines
Brief: Dimerix Ltd Licenses Dmx200 To Everest For China And Asia Region
Brief: Everest Medicine In Agreement With Dimerix To Develop Commercialize DMX-200 In Greater China, South Korea, And Southeast Asia
Brief: Dimerix Seeks Trading Halt
Brief: Dimerix To Conduct Review Of Action3 Statistical Assumptions